Afresa Provides Rapid Suppression Of Endogenous Glucose Production In Diabetics

Mankind has presented Afresa study data at the 45th Annual Meeting of the European Association for the Study of Diabetes.

The data shows that Afresa Inhalation Powder is a well-tolerated, rapid acting insulin able to replicate normal glucose suppression.

Results of the open-label, single-dose, three-way crossover study showed that endogenous glucose production (EGP) was suppressed earlier following Afresa administration compared with subcutaneous insulin lispro and inhaled Exubera in adult patients with type 2 diabetes.

Afresa is a novel, rapid acting mealtime insulin therapy with an action profile that mimics meal-related early insulin release. Based on an extensive phase 2/3 clinical program, a New Drug Application (NDA) is currently under review by the FDA requesting approval to market Afresa Inhalation Powder and the AFRESA Inhaler for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia.

Jay Skyler, professor of division of endocrinology, diabetes & metabolism, and associate director of diabetes research institute at University of Miami Miller School of Medicine, said: “Many people do not appreciate that most of the excess postprandial glucose increase in individuals with diabetes is due to inadequate suppression of endogenous glucose production by the liver. This study demonstrates that more rapid insulin availability better suppresses EGP.”